MUCOSAL ABETA VACCINATION; MODULATING THE IMMUNE RESPONSE

粘膜 ABETA 疫苗接种；

• 批准号: 7349532
• 负责人: CYNTHIA A LEMERE
• 金额: $ 3.5万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-01 至 2007-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7349532
• 关键词: MUCOSAL; ABETA; VACCINATION; MODULATING; IMMUNE

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Abeta immunotherapy has potential for preventing and possibly treating Alzheimer¿s disease (AD) in humans. Studies in genetically-engineered AD mouse models have consistently demonstrated efficacy of the Abeta vaccine both in lowering CNS Abeta and improving cognition without any adverse effects. However, the first human clinical trial was halted due to meningoencephalitis in approximately 6% of patients; recognition of the full-length Abeta immunogen as a self-protein may have attributed to these adverse events. Non-human primates, including Caribbean vervets (Chlorocebus aethiops), have the same amyloid precursor protein (APP) and Abeta as humans, and have age-related cerebral plaque deposition. Thus, they may serve as a better animal model for studying Abeta clearance and immune responses to Abeta vaccination. We are training vervets for behavioral testing of cognitive functions and will begin Abeta vaccination in the next several months. Our goals are to characterize the humoral and cellular immune responses to a novel Abeta vaccine and to determine the vaccine¿s efficacy in lowering Abeta within the nervous system and improving cognition.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。β免疫疗法具有预防和可能治疗人类阿尔茨海默病（AD）的潜力。对基因工程AD小鼠模型的研究一致证明了Abeta疫苗在降低中枢神经系统Abeta和改善认知方面的有效性，而没有任何不良反应。然而，第一次人体临床试验因约6%患者的脑膜脑炎而停止；将全长免疫原识别为自身蛋白可能是导致这些不良事件的原因。非人类灵长类动物，包括加勒比马尾猴（Chlorocebus aethiops），具有与人类相同的淀粉样蛋白前体蛋白（APP）和β，并且具有与年龄相关的脑斑块沉积。因此，它们可以作为研究Abeta清除和对Abeta疫苗免疫反应的更好的动物模型。我们正在训练vervet进行认知功能的行为测试，并将在未来几个月开始接种Abeta疫苗。我们的目标是表征对一种新型Abeta疫苗的体液和细胞免疫反应，并确定疫苗在降低神经系统内的Abeta和改善认知方面的功效。